公司合并 - Ambrx Biopharma, Inc.宣布股东批准与Johnson & Johnson的合并协议[1] - 股东将在交易完成时每股收到28.00美元现金[1] - Ambrx预计将于2024年3月7日左右完成交易[4] 公司业务 - Ambrx是一家临床阶段的生物制药公司，利用扩展的遗传密码技术平台发现和开发下一代抗体药物结合物（ADCs）和其他工程疗法[5] - Ambrx与多个合作伙伴在使用Ambrx技术生成的药物候选品上有临床前和临床合作关系[6] 公司信息披露 - Ambrx定期在其网站上发布对投资者重要的信息[7]

With stocks up 200%, you face a dilemma. While you don’t want to fight momentum, you also don’t want to buy into excessive exuberance and jump into a stock at its top, forced to hold until break-even or sell for a loss down the road. These three companies represent solid picks among the handful of stocks up 200% in 2024. One has a long and fruitful future, buffeted by ongoing enthusiasm for machine learning and advanced computing. The other two represent equity arbitrage plays, and while they may not be 10x ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Ambrx Biopharma Inc. (AMAM) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Ambrx Biopharma Inc. is one of 1069 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks ...

NEW YORK, Feb. 12, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: Ambrx Biopharma has agreed to be acquired by J ...

分组1 - Kuehn Law正在调查以下公司的潜在索赔[1] 分组2 - PGT Innovations同意与MITER Brands合并，每股将获得42.00美元现金[2] 分组3 - Johnson & Johnson同意收购Ambrx Biopharma，每股将获得28.00美元现金[3] 分组4 - Hewlett Packard将以40.00美元现金购买Juniper的所有流通股份，总股权价值约为140亿美元[4]

NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: Callon Petroleum Company (NYSE:CPE) click ...

NEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: Under the proposed transaction, Clearlake ...

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: Ambrx Biopharma, Inc. (Nasdaq: AMAM) Johnson & ...

Ambrx Biopharma (AMAM) signed a definitive agreement with Johnson & Johnson (JNJ) . Per the agreement terms, the pharma giant will acquire all outstanding shares of Ambrx for $28 per share in cash, aggregating to $2.0 billion. A clinical-stage biopharmaceutical company, Ambrx is focused on developing next-generation antibody drug conjugates (ADCs) designed to target multiple cancer indications. Its lead asset, ARX517, targets the prostate- specific membrane antigen (PSMA) expressed in prostate cancer cells. ...

PALM BEACH, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to the report titled "Aging in the United States," published by the Population Reference Bureau, "the number of Americans aged 65 and older is projected to increase more than double over 95 million by the year 2060, and it is expected to rise to approximately 23 percent from 16 percent. Cancer is a non-treatable chronic disease that has posed a challenge to the medical fraternity for decades. The fatal nature of t ...